The final, formatted version of the article will be published soon.
MINI REVIEW article
Front. Endocrinol.
Sec. Cancer Endocrinology
Volume 16 - 2025 |
doi: 10.3389/fendo.2025.1517525
This article is part of the Research Topic Advances in Targeted Therapy and Biomarker Research for Endocrine-Related Cancers, Volume II View all articles
CAR-T Therapy for Endocrine neoplasms: Novel Targets and Combination of Therapies
Provisionally accepted
Fang Wang 1* Ruiqi Zhang 2*
Zhaokai Zhou 2 Run Shi 3*
Fu Peng 4 Shuai Yang 2*
Zhan Wang 2
Pengpeng Zhang 5 Rui Tu 1*
Chun Zhang 6*
Xingchen Liu 1* Jun Cai 1*- 1 Xinyang Central Hospital, Xinyang, China
- 2 First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China
- 3 First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, China
- 4 West China School of Pharmacy, Sichuan University, Chengdu, Sichuan Province, China
- 5 Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
- 6 Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Liaoning Province, China
Endocrine malignancies constitute a heterogeneous tumour group with diverse biological characteristics. While typically indolent, they encompass aggressive types and presence of any metastatic sign indicates a high probability of recurrence and a diminished response to conventional therapies. Chimeric antigen receptor (CAR)-T cell immunotherapy has constituted a revolutionary advance in cancer treatment and exhibited significant potential for application in endocrine cancer. However, limited effectiveness was displayed in clinical application, which necessitates the exploration of novel modalities. Identification of specific and safe targets for endocrine cancer is the initial stage towards establishing a successful CAR-T treatment. Various therapies under investigation offer potential enhancements to CAR T cell efficacy through diverse mechanisms. Herein, we summarize recent advances in identifying targets of endocrine cancer for CAR therapy and provide an overview of combinatorial approaches.
Keywords: Endocrine neoplasms, Chimeric antigen receptor T cell, Immunotherapy, Combined immunotherapy, clinical trials
Received: 26 Oct 2024; Accepted: 23 Jan 2025.
Copyright: © 2025 Wang, Zhang, Zhou, Shi, Peng, Yang, Wang, Zhang, Tu, Zhang, Liu and Cai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Fang Wang, Xinyang Central Hospital, Xinyang, China
Ruiqi Zhang, First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan Province, China
Run Shi, First Affiliated Hospital, Nanjing Medical University, Nanjing, 210029, Jiangsu Province, China
Shuai Yang, First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan Province, China
Rui Tu, Xinyang Central Hospital, Xinyang, China
Chun Zhang, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Liaoning Province, China
Xingchen Liu, Xinyang Central Hospital, Xinyang, China
Jun Cai, Xinyang Central Hospital, Xinyang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.